synHSV™ is capable of delivering up to 30x the payload of AAV. We can deliver big genes, genomic genes, and multiple genes, unlocking the promise of polygenic medicine.
83% of genes are too big for AAV
uCell™ is an immune silencing technology that enables iPSCs to be used as a renewable source for cell therapies. This substantially reduces the cost of goods associated with patient- or pooled donor-derived cells, improves product consistency and volume, and enables extensive genome engineering.
DropSynth™ enables the efficient assembly of large libraries of gene-size fragments. These can be used to explore protein sequence space in a manner that is more efficient, cost-effective, and comprehensive than directed evolution.
Writing DNA is a million times more expensive than sequencing. Reducing the cost of writing to those of reading will enable the era of genome writing, which has the potential to disrupt multiple industries.